All bites
Sector SignalHealthtech·NotableSignal 45

Global biotech startup funding holds steady at $36B-$40B

Company
Crunchbase
Signal type
Sector Signal
Date
Location
🇺🇸 the US
Sector
Biotech
Investors
Undisclosed

What happened

Global venture funding to biotech startups has maintained between $36 billion and $40 billion annually in recent years, per Crunchbase data. The sector remains on track to match that pace in 2026 despite the surge in AI funding.

Why it matters

Biotech's steady annual capture of $36B to $40B demonstrates resilient institutional capital allocation to life sciences even as generalist venture funds pivot heavily toward generative AI. The sector's specialized investor base and distinct regulatory catalysts insulate it from broader software funding swings.

What to watch

Whether generalist venture funds re-enter early-stage therapeutics rounds or leave the sector predominantly to specialized healthcare firms.

VCBites Signal

57/ 100
Notable signal

Why this score: Sustained annual funding between $36B and $40B shows deep macro stability in life sciences, though static growth prevents a higher signal score.

VCBites' internal significance rating (0-100) — our editorial read, not a market-standard metric. VC Bites' assessment of the significance of this development to the venture ecosystem. Not investment advice.

Who should care?

  • Biotech Founders
  • VC Investors
  • Healthcare Operators
  • LPs

Source

This is an original short summary. Read the full reporting at the original source.

Read the original story on Crunchbase News

Share the signal

VC Bites

Global biotech startup funding holds steady at $36B-$40B

VCBITES SIGNAL: 57 / 100

Why it matters

Biotech's steady annual capture of $36B to $40B demonstrates resilient institutional capital allocation to life sciences even as generalist venture funds pivot heavily toward generative AI. The sector's specialized investor base and distinct regulatory catalysts insulate it from broader software funding swings.

VC Bites · Venture capital signals, explained.

The post text is copied to your clipboard so you can paste it alongside the link.

More Healthtech bites

UndisclosedHealthtechCanada·BackgroundSignal 38 · Canada market

DropGenie raises $5M USD

Biotech startup DropGenie has secured $5 million USD in funding with backing from BDC. The company operates in Montréal and Boston to accelerate biological data extraction.

Why it matters

Operating across Montréal and Boston enables DropGenie to bridge Canadian research capabilities with established US biopharma networks.

What to watch

Scaling of biological data extraction capabilities and expansion into US commercial partnerships.

UndisclosedHealthtech·NotableSignal 46

Even Healthcare reaches $300M valuation in Khosla Ventures-led round

Even Healthcare reached a $300 million valuation in a new financing round led by Khosla Ventures. The company intends to use the capital to expand its hospital network in India.

Why it matters

Khosla Ventures' backing of Even Healthcare at a $300 million valuation signals sustained tier-1 US investor appetite for tech-enabled physical healthcare networks in India. Blending digital management with physical hospital infrastructure represents a capital-intensive evolution of standard healthtech delivery in emerging markets.

What to watch

Whether healthtech operators expanding into physical hospital footprints can sustain software-like margins while managing heavy capital expenditures.

Series AHealthtechCanada·NotableSignal 59 · Canada market

Altay Therapeutics Closes $37M Series A

Altay Therapeutics, Inc. closed a $37 million Series A financing round to advance its DX5057 drug candidate for FSHD. The financing was co-led by Sound and supported by SOLVE FSHD.

Why it matters

Dedicated funding for rare disease targets continues to attract substantial early-stage capital when backed by specialized funds. A $37 million Series A provides sufficient runway to push lead candidate DX5057 into initial clinical validation phases.

What to watch

Clinical safety and preliminary efficacy data readouts from early trials of lead candidate DX5057.